首页> 外文期刊>Drug safety: An international journal of medical toxicology and drug experience >Issues Related to Monitoring the Safety of Over-The-Counter (OTC) Medicines.
【24h】

Issues Related to Monitoring the Safety of Over-The-Counter (OTC) Medicines.

机译:与监控非处方药(OTC)安全性有关的问题。

获取原文
获取原文并翻译 | 示例
       

摘要

Pharmaceutical advances over the past 50 years have benefited many people in terms of disease prevention and management. However, probably without exception, most pharmaceutical products can cause adverse consequences of varying severity and frequency.In the last 10 years, many medicines that were originally prescription only have now become available over the counter (OTC), either from pharmacies or other general retail outlets. The volume and value of OTC medicine sales have increased accordingly. These switches have been well regulated and based on clear criteria and evidence of safety. Benefits of the changes include increased convenience to patients, greater self-management of minor ailments and a reduction in government drug expenditure.However, there are important differences between medicines supplied OTC and on medical prescription. With OTC medicines there is generally less healthcare professional input into the recommendation or ongoing monitoring of use. There is an absence of records per se, or linkage to other medication records elsewhere, and most countries allow direct-to-consumer advertising of the product. Taken together these differences can result in inappropriate expectations, demand and use of the OTC medicines, with limited opportunity for ongoing patient follow-up and monitoring of safety.Methodologies for pharmacy-based epidemiological studies of OTC medicines need to be developed. Studies should be large enough to detect associations that might exist, and to consider other explanations for associations such as chance, bias or confounding. There have already been some pilot studies with encouraging results with respect to follow-up rates. Outcome data however have usually been self-reported and the studies have lacked a suitable comparison group.Purchasers and suppliers of OTC medicines should also be made aware of, and encouraged to use, existing systems for spontaneous reporting of suspected adverse events, such as the Yellow Card Scheme in the UK.While available OTC medicines are perceived to be generally safe, problems have occasionally arisen with some earlier switched products (e.g. terfenadine). There have also been concerns about some traditional herbal and homeopathic remedies such as St John's wort. While such adverse events are rare, they emphasise the need for healthcare professionals and the public to understand and manage such risks. Many doctors are unaware of the range of OTC preparations available, and therefore do not consider them as a possible cause of presenting symptoms. Neither do they take them into account when making a new prescribing decision. The public need to be aware that OTC medicines should be treated with the same care as prescribed medicines, and that advice on recommended dose, contraindications and interactions should be adhered to.
机译:在疾病预防和管理方面,过去50年来制药业的进步使许多人受益。但是,可能无一例外,大多数药品可能会导致严重程度和频率变化的不良后果。在过去的10年中,许多原本只能处方的药物现在可以通过药店或其他一般零售渠道在柜台(OTC)购买网点。场外药品的销售量和价值也相应增加。这些开关已经过良好调节,并基于明确的标准和安全证据。这些变化的好处包括为患者提供更多便利,对小病的自我管理能力增强以及政府药品支出的减少。然而,非处方药和处方药之间存在重要差异。使用OTC药物时,通常很少有医疗保健专业人员对推荐或使用情况进行持续监控。本身没有记录,也没有与其他地方的其他药物记录的链接,并且大多数国家/地区允许产品直接面向消费者投放广告。这些差异加在一起可能导致对OTC药物的期望,需求和使用不当,而对患者进行后续随访和安全性监控的机会有限。需要开发基于药物的OTC药物流行病学研究方法。研究应足够大,以发现可能存在的关联,并考虑关联的其他解释,例如机会,偏见或混淆。已经进行了一些试验研究,其随访率令人鼓舞。然而,结果数据通常是自我报告的,并且研​​究缺乏合适的比较组。还应使非处方药的购买者和供应商了解并鼓励使用现有的系统,用于自发报告可疑不良事件,例如英国的黄卡计划。尽管人们认为可用的非处方药通常是安全的,但某些较早转换的产品(例如特非那定)偶尔会出现问题。人们还担心一些传统的草药和顺势疗法,例如圣约翰草。尽管此类不良事件很少见,但它们强调医疗保健专业人员和公众需要了解和管理此类风险。许多医生不知道可用的OTC制剂的范围,因此不认为它们是出现症状的可能原因。在做出新的处方决定时,他们也不考虑它们。公众需要意识到,非处方药应与处方药一样接受治疗,并应遵循建议剂量,禁忌症和相互作用的建议。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号